BiotechTube

PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scalp Psoriasis

Conditions

Scalp Psoriasis

Trial Timeline

Mar 29, 2019 → Feb 17, 2022

NCT ID
NCT03897088

About PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension

PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension is a phase 3 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03897088. Target conditions include Scalp Psoriasis.

What happened to similar drugs?

0 of 5 similar drugs in Scalp Psoriasis were approved

Approved (0) Terminated (0) Active (5)
🔄DSXS + PlaceboSun PharmaceuticalPhase 3
🔄DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
🔄Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
🔄Secukinumab 300 mg + PlaceboNovartisPhase 3
🔄Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03897088Phase 3Completed

Competing Products

7 competing products in Scalp Psoriasis

See all competitors
ProductCompanyStageHype Score
DSXS topical productSun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
40
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspensionSun PharmaceuticalPhase 1
29
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
40
Secukinumab 300 mg + PlaceboNovartisPhase 3
40
Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3
34